Novavax (NASDAQ: NVAX) reported Q4 EPS of ($1.44), $0.99 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $291 million versus the consensus estimate of $321.97 million.

GUIDANCE:

Novavax sees FY2024 revenue of $0.8-1 billion, versus the consensus of $0.97 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.